References

• Agid, O., Crespo-Facorro, B., de Bartolomeis, A., et al. (2024). Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice. European Neuropsychopharmacology, 84, 35–47. https://pubmed.ncbi.nlm.nih.gov/38657339/
• Qubad, M., & Bittner, R. A. (2023). Second to none: Rationale, timing, and clinical management of clozapine use in schizophrenia. Therapeutic Advances in Psychopharmacology, 13, 20451253231158152. https://doi.org/10.1177/20451253231158152
• Oloyede, E., Blackman, G., Mantell, B., Harris, E., Williams, J., Taylor, D., MacCabe, J., & McGuire, P. (2023). What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians. Schizophrenia, 9(1), 26. https://doi.org/10.1038/s41537-023-00353-0
• Smessaert, S., De Hert, M., & Correll, C. U. (2024). Evaluating monitoring guidelines of clozapine-induced adverse effects: A systematic review. CNS Drugs, 38(4), 287–306. https://doi.org/10.1007/s40263-024-01067-2